HIGHLIGHTS
- who: Oncology and collaborators from the United States United States United States have published the article: Journal of Health Economics and Outcomes Research, in the Journal: (JOURNAL) of March/02,/2022
- what: This study was conducted to evaluate treatment patterns, healthcare resource utilization (HRU), and healthcare costs in patients with CML who received a 3L+. These studies reported average total all-cause healthcare costs ranging between approximately $10 000 to $13 000 PPPM whereas this study reported costs ranging between $15 206 PPPM (for the 3L) and $19 546 PPPM (for the 4L). This study . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.